Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node–Positive and High-Risk Lymph Node–Negative Breast Cancer (E5103)

PURPOSE: Bevacizumab improves progression-free survival but not overall survival in patients with metastatic breast cancer. E5103 tested the effect of bevacizumab in the adjuvant setting in patients with human epidermal growth factor receptor 2–negative disease. PATIENTS AND METHODS: Patients were a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Miller, Kathy D., O’Neill, Anne, Gradishar, William, Hobday, Timothy J., Goldstein, Lori J., Mayer, Ingrid A., Bloom, Stuart, Brufsky, Adam M., Tevaarwerk, Amye J., Sparano, Joseph A., Le-Lindqwister, Nguyet Anh, Hendricks, Carolyn B., Northfelt, Donald W., Dang, Chau T., Sledge, George W.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6118403/
https://ncbi.nlm.nih.gov/pubmed/30040523
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2018.79.2028
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados